Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Ikarian Capital LLC

Ikarian Capital LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 28.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,030,277 shares of the company’s stock after buying an additional 230,000 shares during the quarter. Tarsus Pharmaceuticals accounts for 4.6% of Ikarian Capital LLC’s holdings, making the stock its 2nd largest holding. Ikarian Capital LLC owned approximately 2.71% of Tarsus Pharmaceuticals worth $33,886,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Cowen AND Company LLC grew its stake in shares of Tarsus Pharmaceuticals by 3.5% in the second quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock valued at $59,725,000 after buying an additional 74,855 shares in the last quarter. Jennison Associates LLC boosted its holdings in Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares during the period. Vanguard Group Inc. boosted its holdings in Tarsus Pharmaceuticals by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock valued at $66,398,000 after purchasing an additional 231,131 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after purchasing an additional 77,825 shares during the period. Finally, Driehaus Capital Management LLC boosted its holdings in Tarsus Pharmaceuticals by 126.1% in the second quarter. Driehaus Capital Management LLC now owns 364,463 shares of the company’s stock valued at $9,906,000 after purchasing an additional 203,300 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Down 3.9 %

NASDAQ:TARS traded down $2.03 during mid-day trading on Tuesday, reaching $50.42. 604,459 shares of the stock were exchanged, compared to its average volume of 740,207. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a 50 day simple moving average of $41.05 and a 200-day simple moving average of $33.34. Tarsus Pharmaceuticals, Inc. has a 1 year low of $15.60 and a 1 year high of $52.99.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Finally, Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.